06/27/2024 | Press release | Distributed by Public on 06/27/2024 15:30
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 27, 2024, SAB Biotherapeutics, Inc., doing business as SAB BIO (the "Company" or "SAB"), held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). The total number of shares of common stock entitled to vote at the Annual Meeting was 9,229,208, and there were 6,806,137 shares present in person or by proxy at the Annual Meeting, which represented approximately 73.40% of the outstanding shares entitled to vote at the Annual Meeting and which constituted a quorum for the transaction of business.
At the Annual Meeting, the shareholders voted to:
The voting results on these proposals were as follows:
Proposal 1: Election of three Class III directors
Director |
Votes For |
Withheld |
Broker Non-Votes |
||||
Samuel J. Reich |
5,080,387 |
420,707 |
1,305,043 |
||||
Christine Hamilton |
4,890,928 |
610,166 |
1,305,043 |
||||
Eddie J. Sullivan |
5,151,258 |
349,836 |
1,305,043 |
Proposal 2: Approval of Plan Amendment
Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
||||
4,172,299 |
1,325,194 |
3,601 |
1,305,043 |
Proposal 3: Ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024
Votes For |
Votes Against |
Abstentions |
|||
6,779,831 |
13,530 |
12,776 |